News | May 08, 2014

Health Canada Approves Abbott's MitraClip Device

Minimally invasive treatment can improve symptoms, quality of life for MR patients too high risk for surgery

May 8, 2014 — Abbott announced its catheter-based MitraClip therapy has received Health Canada approval, providing physicians in Canada with the treatment option that can significantly improve symptoms, disease progression and quality of life for certain people with mitral regurgitation (MR).

The MitraClip device has been approved for people with degenerative MR who are too high risk for mitral valve surgery based on evaluation by heart experts. Degenerative MR is a type of MR caused by an anatomic defect of the mitral valve of the heart. Treatment with the MitraClip device can be effective in reducing the symptoms associated with severe MR, such as shortness of breath and fatigue, which may help people lead a more active lifestyle. 

MR can raise the risk of irregular heartbeats, stroke and heart failure. Open-heart mitral valve surgery is the standard-of-care treatment, but many patients are too high risk for an invasive procedure. Medications for the condition are limited to reducing symptoms and do not have the ability to stop the progression of the disease.

"As cardiac surgeons, we often see patients with mitral regurgitation who are too frail or sick for mitral valve surgery and are severely limited in their daily activities due to their disease," said Gideon Cohen, M.D., Ph.D., FRCS, chief, division of cardiac surgery, Sunnybrook Health Sciences Centre, University of Toronto. "The MitraClip system provides a new catheter-based, minimally invasive treatment option for many of these patients, addressing an important unmet need and helping them regain their quality of life."

Multiple trials, published reports and registries of patients treated with the MitraClip device consistently demonstrate a positive safety profile, reduction in mitral regurgitation, improvement in symptoms and reduction in hospitalizations for heart failure.

"Patients treated with the MitraClip device can have dramatic improvements when their mitral regurgitation is reduced and their heart can pump blood more efficiently," said Anita Asgar, M.D., FRCPC, FACC, cardiologist, Montreal Heart Institute. "Many of these patients have suffered with mitral regurgitation without access to other treatment options, making the approval of the MitraClip device in Canada tremendous news as it offers a new alternative to these patients.”

Abbott's MitraClip repairs the mitral valve without the need for an invasive surgical procedure. The device is delivered to the heart through the femoral vein, and once implanted, allows the heart to pump blood more efficiently, thereby relieving symptoms and improving quality of life. Patients undergoing MitraClip treatment typically experience short recovery times and short hospital stays of two to three days.

"Health Canada approval of MitraClip marks an important milestone in bringing this first-of-its-kind therapy to many patients who have no other viable treatment options for their mitral regurgitation," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, medical affairs, and chief medical officer, Abbott Vascular. "We look forward to making this technology available to specialized centers in Canada with teams of heart doctors experienced in the management of patients with mitral valve disease, with the aim of providing people with the best possible treatment options." 

For more information: www.abbott.ca

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Overlay Init